Skip to content
Home/Companies/MedTech/CVRx

CVRx

MedTech·US·Exited 2021·Held 8yr
Entry
2013
Hold
8yr
Exit
2021

Who owns CVRx?

CVRx was owned by Ysios Capital Partners through Ysios BioFund II Innvierte (2016 vintage) from 2013 to 2021, exited via IPO.

Hand-verified · updated 2026-08-03

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund II Innvierte · 2016 · Life Sciences VC

Key facts

HQUS
SectorMedTech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from Ysios BioFund II Innvierte

Other portfolio companies in the same fund.

Anaconda Biomed
Anaconda Biomed
Active
MedTechES· 2017
Babyscripts
Babyscripts
Active
HealthTechUS· 2017
Prexton Therapeutics
Exited 2018
BiotechCH· 2017
to
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFR· 2017
Xeltis
Xeltis
Active
MedTechNL· 2017
AELIX Therapeutics
AELIX Therapeutics
Active
BiotechES· 2016

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Optos
Exited 2015
Amadeus Capital PartnersUK
to
Axomove
Axomove
Active
Go CapitalFrance· 2026
Bioliberty
Active
Scottish National Investment BankUK· 2026
CertHub
Active
Cusp Capital PartnersGermany· 2026
Clee Medical
Clee Medical
Active
High-Tech Gruenderfonds (HTGF)Switzerland· 2026
CollimateHealth
Active
Caesar Ventures ManagementGermany· 2026
Track CVRx

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on CVRx.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue